版本:
中国

BRIEF-Catalyst Biosciences gets IND approval in South Korea for subcutaneous factor IX program

March 28 Catalyst Biosciences Inc

* Catalyst Biosciences announces IND approval in South Korea for next-generation subcutaneous factor IX program

* ISU ABXIS plans to initiate phase 1/2 proof-of-concept study in individuals with severe hemophilia B in Q2 of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐